Le Lézard
Classified in: Health, Business
Subjects: ERN, ACC

Elekta: Interim report, May-January 2021/22


STOCKHOLM, Feb. 24, 2022 /PRNewswire/ -- The demand for Elekta's solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta's strongest order backlog ever. However, the global supply chain challenges remained, and revenue and margins came in lower than last year. We are fully committed to returning to revenue growth and margin expansion.

Gustaf Salford
President and CEO
 

Third quarter         

First nine months          

Significant events after the quarter           

Group summary










Q3



First nine months


SEK M

2021/22


2020/21

?


2021/22


2020/21

?

Gross order intake

4,441


3,954

8%4


12,467


12,032

5%4

Net sales

3,602


3,581

-3%4


10,309


10,096

4%4

Gross margin

36.7%


38.7%

-2 ppts


37.5%


41.6%

-4,1 ppts

EBIT 1

340


468

-27%


1,074


1,361

-21%

EBIT margin

9.4%


13.1%

-3,6 ppts


10.4%


13.5%

-3,1 ppts

Cash flow 2

187


496

-62%


-173


886

-120%

Earnings per share, SEK 3

0.60


0.84

-29%


1.93


2.39

-19%











1Including the contribution to Elekta Foundation of SEK 35 M reported in Q3 2021/22.




2After continuous investments.








3Before/after dilution.









4Based on constant currency.








For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: [email protected]
Time zone: CET: Central European Time

Tobias Hägglöv, CFO
Tel: +46 76 107 47 99, e-mail: [email protected]
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on February 24, 2022. (REGMAR) 

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/elekta/r/interim-report--may-january-2021-22,c3513327

The following files are available for download:

https://mb.cision.com/Main/35/3513327/1540009.pdf

Elekta Q3 Report 21_22

https://news.cision.com/elekta/i/group-summary-q3-2021-22,c3016428

Group summary Q3 2021-22

SOURCE Elekta


These press releases may also interest you

at 06:30
The global microscopy market is poised for significant growth, expected to reach USD 10.6 billion by 2029 from USD 8.1 billion in 2024, growing at a CAGR of 5.4%. Key drivers include rising cases of chronic diseases necessitating effective...

at 06:25
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...



News published on and distributed by: